Umeclidinium bromide
Umeclidinium bromide Basic information
- Product Name:
- Umeclidinium bromide
- Synonyms:
-
- DIPHENYL-[1-(2-PHENYLMETHOXYETHYL)-1-AZONIABICYCLO[2.2.2]OCTAN-4-YL]METHANOL;BROMIDE
- CS-1562
- Umeclidinium bromide(GSK573719A)
- 1-[2-(Benzyloxy)ethyl]-4-(hydroxydiphenylmethyl)-1-quinuclidinium Bromide
- Umeclinidium bromide
- GSK573719A;GSK-573719A;GSK 573719A
- 1-(2-(benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)quinuclidin-1-ium bromide
- GSK573719A
- CAS:
- 869113-09-7
- MF:
- C29H34BrNO2
- MW:
- 508.48976
- EINECS:
- 638-761-1
- Product Categories:
-
- API
- 869113-09-7
- Mol File:
- 869113-09-7.mol
Umeclidinium bromide Chemical Properties
- Melting point:
- >231°C (dec.)
- storage temp.
- under inert gas (nitrogen or Argon) at 2-8°C
- solubility
- DMSO (Slightly), Methanol (Slightly), Water (Slightly)
- form
- Solid
- color
- White to Off-White
- Stability:
- Hygroscopic
Umeclidinium bromide Usage And Synthesis
Description
Umeclidinium bromide is a long-acting muscarinic acetylcholine antagonist developed by GlaxoSmithKline and approved by the US FDA at the end of 2013 for use in combination with vilanterol, a b2 agonist, for the treatment of chronic obstructive pulmonary disease. Due to umeclidinium’s poor oral bioavailability, the drug is administrated by inhalation as dry powder.
Uses
Umeclidinium Bromide is considered as a potentially long-acting antimuscarinic agent.
Definition
ChEBI: A quaternary ammonium salt that is the bromide salt of umeclidinium. Used in combination with vilanterol for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.
Synthesis
Commercially available ethyl isonipecotate (278) was alkylated with 1-bromo-2-chloroethane in the presence of K2CO3 in acetone to give ethyl 1-(2-chloroethyl)piperidine-4-carboxylate (279). This material was then treated with lithium diisopropylamine (LDA) in THF to affect a transannular substitution reaction resulting in the cyclized quinuclidine 280 in 96% yield. Excess of phenyllithium was added to ester 280 in THF starting at low temperature then gradually warming to room temperature to give tertiary alcohol 281 in 61% yield. Amine 281 was finally alkylated with benzyl 2- bromoethyl ether (282) in MeCN/CHCl3 at elevated temperatures to afford umeclidinium bromide (XXXV) in 69% yield.
References
[1] salmon m, luttmann m a, foley j j, et al. pharmacological characterization of gsk573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. journal of pharmacology and experimental therapeutics, 2013, 345(2): 260-270.
Umeclidinium bromideSupplier
- Tel
- 0531-82375880 15098789112
- 2710825968@qq.com
- Tel
- 010-56380788-8515 16619769925
- wch013@bionna.cn
- Tel
- 021-50689757 15618953996
- sales@goyic.com
- Tel
- sales@boylechem.com
- Tel
- 0757-86329057 18934348241
- sales4.gd@hwrkchemical.com